These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1771322)

  • 1. [New developments of antiplatelet drugs].
    Ambrosi P; George F; Faugere G; Habib G; Chicheportiche C; Luccioni R
    Rev Med Interne; 1991; 12(5):389-94. PubMed ID: 1771322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapy.
    Schafer AI
    Am J Med; 1996 Aug; 101(2):199-209. PubMed ID: 8757361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antithrombotic drugs in development.
    Verstraete M; Zoldhelyi P
    Drugs; 1995 Jun; 49(6):856-84. PubMed ID: 7641602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of antiplatelet drugs in vitro: distinct effects of cAMP-elevating drugs and GPIIb/IIIa antagonists on thrombin-induced platelet responses.
    Matsumoto Y; Marukawa K; Okumura H; Adachi T; Tani T; Kimura Y
    Thromb Res; 1999 Jul; 95(1):19-29. PubMed ID: 10403683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Haemostasis and antithrombotic drugs: pharmacology and novel therapeutic approaches].
    Schrör K
    Hamostaseologie; 2006 May; 26(2):104-5. PubMed ID: 16676051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet agents in stroke prevention. combination therapy: present and future.
    Weksler BB
    Cerebrovasc Dis; 2000; 10 Suppl 5():41-8. PubMed ID: 11096182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in antiplatelet and antithrombotic therapy.
    Verstraete M
    Eur Heart J; 1995 Nov; 16 Suppl L():16-23. PubMed ID: 8869014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet drugs. A comparative review.
    Schrör K
    Drugs; 1995 Jul; 50(1):7-28. PubMed ID: 7588091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Platelet aggregation disorders].
    Patscheke H
    Hamostaseologie; 2003 Nov; 23(4):181-5. PubMed ID: 14603382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiplatelet agents and their therapeutic use].
    Lecompte T
    Rev Prat; 1999 Oct; 49(15):1627-33. PubMed ID: 10581992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticoagulants of primary haemostasis].
    Kössler J; Steigerwald U; Walter U
    Hamostaseologie; 2009 Aug; 29(3):274-8. PubMed ID: 19644598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Haemostasis. Aspirin and clopidogrel platelet resistances].
    Fontana P; Berdagué P; Reny JL
    Rev Med Suisse; 2006 Jan; 2(47):25-9. PubMed ID: 16465941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiplatelet agents (inhibitors of platelet function) orally administered. Bases for their practical use in coronary artery disease].
    Lecompte T; de Maistre E
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1507-13. PubMed ID: 9092411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C
    Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
    Takiguchi Y; Wada K; Nakashima M
    Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
    Mousa SA; Bozarth JM; Forsythe MS; Jackson SM; Leamy A; Diemer MM; Kapil RP; Knabb RM; Mayo MC; Pierce SK
    Circulation; 1994 Jan; 89(1):3-12. PubMed ID: 8281661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antiplatelet drugs: beyond aspirin and clopidogrel.
    Siddique A; Butt M; Shantsila E; Lip GY
    Int J Clin Pract; 2009 May; 63(5):776-89. PubMed ID: 19392926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triggering by Paf-acether and adrenaline of cyclo-oxygenase-independent platelet aggregation.
    Fouque F; Vargaftig BB
    Br J Pharmacol; 1984 Nov; 83(3):625-33. PubMed ID: 6439269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.